{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:41:35Z","timestamp":1768322495258,"version":"3.49.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T00:00:00Z","timestamp":1451347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0145885","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T13:52:40Z","timestamp":1451397160000},"page":"e0145885","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France"],"prefix":"10.1371","volume":"10","author":[{"given":"Gilles","family":"Pialoux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Despi\u00e9gel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Espinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Cawston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Finkielsztejn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Laurisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,12,29]]},"reference":[{"issue":"3","key":"ref1","first-page":"461","article-title":"Improved survival in HIV-infected persons: consequences and perspectives","volume":"60","author":"N Lohse","year":"2007","journal-title":"JAntimicrobChemother"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/QAD.0b013e32833a3946","article-title":"Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals","volume":"24","author":"Al van Sighem","year":"2010","journal-title":"AIDS"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1468-1293.2010.00861.x","article-title":"The evolving burden of HIV infection compared with other chronic diseases in northern Italy","volume":"12","author":"M Magoni","year":"2011","journal-title":"HIV Med"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/QAD.0b013e32834dce6e","article-title":"Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults","volume":"26","author":"CE Sloan","year":"2012","journal-title":"AIDS"},{"key":"ref5","unstructured":"Morlat P. Prise en charge m\u00e9dicale des personnes vivant avec le VIH\u2014Actualisation 2014 du Rapport 2013\u2014Sous la direction du Pr Phillipe Morlat et sous l&apos;\u00e9gide du CNS et de l&apos;ANRS 2014 [updated 2014]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.sante.gouv.fr\/IMG\/pdf\/experts-vih_actualisations2014.pdf\" xlink:type=\"simple\">http:\/\/www.sante.gouv.fr\/IMG\/pdf\/experts-vih_actualisations2014.pdf<\/ext-link>."},{"issue":"13","key":"ref6","first-page":"853","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"FJ Palella Jr.","year":"1998","journal-title":"HIV Outpatient Study Investigators. NEnglJMed"},{"key":"ref7","unstructured":"Morlat P. Prise en charge m\u00e9dicale des personnes vivant avec le VIH-Recommandations du groupe d&apos;experts-Rapport 2013-Sous la direction du Pr Phillipe Morlat et sous l&apos;\u00e9gide du CNS et de l&apos;ANRS. 2013 2013. Report No."},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(11)70248-1","article-title":"Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study","volume":"12","author":"D Castagliola","year":"2012","journal-title":"Lancet InfectDis"},{"key":"ref9","unstructured":"EPAR summary for the public\u2014Tivicay, dolutegravir: European Medicines Agency (EMA); 2013 [updated 2013]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002753\/WC500160681.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002753\/WC500160681.pdf<\/ext-link>."},{"issue":"9893","key":"ref10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"P Cahn","year":"2013","journal-title":"Lancet"},{"key":"ref11","unstructured":"A methodological Guide\u2014Choices in Methods for Economic Evaluation. Haute Autorit\u00e9 de Sant\u00e9 (HAS), 2012 2012. Report No."},{"issue":"2","key":"ref12","first-page":"80","article-title":"A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals","volume":"11","author":"FC Kuhne","year":"2010","journal-title":"HIV ClinTrials"},{"issue":"4","key":"ref13","first-page":"416","article-title":"The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy","volume":"165","author":"MA d'Arminio","year":"2005","journal-title":"ArchInternMed"},{"key":"ref14","unstructured":"Pharmacoeconomic Guidelines Around the world: International Society for Pharmacoeconomics and Outcomes Research; 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ispor.org\/PEguidelines\/index.asp\" xlink:type=\"simple\">http:\/\/www.ispor.org\/PEguidelines\/index.asp<\/ext-link>."},{"key":"ref15","unstructured":"Dolutegravir 50 mg Comprim\u00e9 pellicul\u00e9 - Rapport de synth\u00e8se Autorisation Temporaire d&apos;Utilisation (ATU) Nominative (NPP report\u2014February 2013). ViiV Healthcare, 2013 2\/2013. Report No."},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"DA Cooper","year":"2008","journal-title":"NEnglJMed"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"RT Steigbigel","year":"2008","journal-title":"NEnglJMed"},{"issue":"3","key":"ref18","first-page":"395","article-title":"Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients","volume":"16","author":"JM Schapiro","year":"2011","journal-title":"AntivirTher"},{"issue":"4","key":"ref19","first-page":"605","article-title":"Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials","volume":"50","author":"RT Steigbigel","year":"2010","journal-title":"ClinInfectDis"},{"key":"ref20","unstructured":"Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Wan H, Zhao J, et al., editors. Final 5-Year Results of the BENCHMRK Studies: Sustained Antiretroviral Effect of Raltegravir, and Exploratory Analysis of Late Outcomes Based on Early Virologic Response. XIX International AIDS Conference; 2012."},{"issue":"5","key":"ref21","first-page":"558","article-title":"Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2","volume":"55","author":"WD Hardy","year":"2010","journal-title":"JAcquirImmuneDeficSyndr"},{"issue":"14","key":"ref22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"RM Gulick","year":"2008","journal-title":"NEnglJMed"},{"issue":"4","key":"ref23","first-page":"404","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials","volume":"40","author":"M Nelson","year":"2005","journal-title":"JAcquirImmuneDeficSyndr"},{"issue":"5","key":"ref24","first-page":"259","article-title":"A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study","volume":"12","author":"J Reekie","year":"2011","journal-title":"HIVMed"},{"key":"ref25","unstructured":"Base des M\u00e9dicaments et Informations Tarifaires: Assurance Maladie\u2014ameli.f; 2015 [updated 3\/19\/2015; cited 2014 10\/30\/2014]."},{"key":"ref26","unstructured":"Les tarifs conventionnels\u2014Tarifs applicables aux pharmaciens biologistes: Assurance Maladie en ligne\u2014ameli.fr; 2011 [updated 9\/6\/2011; cited 2014 10\/30\/2014]."},{"key":"ref27","unstructured":"Les tarifs conventionnels: Assurance Maladie en ligne\u2014ameli.fr; 2012 [updated 6\/21\/2012; cited 2014 10\/30\/2014]."},{"key":"ref28","unstructured":"Biologie M\u00e9dicale\u2014Nomenclature des actes: Caisse Nationale de l&apos;Assurance Maladie des Travailleurs Salari\u00e9s; 2014 [updated 9\/2014; cited 2014 10\/30\/2014]."},{"key":"ref29","unstructured":"Remboursement d&apos;une consultation m\u00e9dicale\u2014Consultation du m\u00e9decin correspondant (pour un suivi r\u00e9gulier\u2014Sp\u00e9cialiste secteur 1 ou secteur 2 avec option de coordination: Service-Public.fr; 2014 [updated 10\/8\/2014; cited 2014 10\/30\/2014]."},{"key":"ref30","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"12","author":"F Raffi","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"F Raffi","year":"2013","journal-title":"Lancet InfectDis"},{"key":"ref32","unstructured":"Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Guttierez F, et al., editors. Dolutegravir (DTG; S\/GSK1349572) + abacavir\/lamivudine once daily statistically superior to tenofovir\/emtricitabine\/efavirenz: 48-week results\u2014SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2012 9\/9\/2012. San Francisco2012."},{"key":"ref33","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","author":"B Clotet","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"ref34","first-page":"S93","article-title":"Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection","volume":"18","author":"AD Paltiel","year":"1998","journal-title":"A"},{"issue":"7","key":"ref35","first-page":"1144","article-title":"A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy","volume":"11","author":"TL Kauf","year":"2008","journal-title":"ValueHealth"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAD.0b013e32834e87e6","article-title":"Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection","volume":"26","author":"J Mauskopf","year":"2012","journal-title":"AIDS"},{"issue":"6","key":"ref37","first-page":"627","article-title":"Cost-effectiveness of raltegravir in HIV\/AIDS","volume":"11","author":"MA Chaudhary","year":"2011","journal-title":"ExpertRevPharmacoeconOutcomesRes"},{"key":"ref38","unstructured":"Despi\u00e9gel N, Anger D, Martin M, Monga N, Cui Q, Gilchrist K, et al., editors. Assessment of real-life predictive power of a new cost-effectiveness model in HIV: antiretroviral analysis by Monte Carlo individual simulation (ARAMIS-DTG)\u2014PIN 462014."},{"key":"ref39","unstructured":"Bases de donn\u00e9es BDM Indice des prix \u00e0 la consommation Secteurs conjoncturels (annuel, ensemble des m\u00e9nages, m\u00e9tropole, base 1998)\u2014Services de sant\u00e9: Institut national de la statistique et des \u00e9tudes \u00e9conomiques (INSEE); 2013 [updated 2013]."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0145885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T12:52:06Z","timestamp":1540299126000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0145885"}},"subtitle":[],"editor":[{"given":"Cristian","family":"Apetrei","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,29]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0145885","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,29]]}}}